Journal of Clinical Oncology, Vol 17, Issue 5
(May), 1999: 1482
© 1999 American Society for Clinical Oncology
Estrogen Replacement Therapy After Localized Breast Cancer: Clinical Outcome of 319 Women Followed Prospectively
Rena Vassilopoulou-Sellin,
Lina Asmar,
Gabriel N. Hortobagyi,
Mary Jean Klein,
Marsha McNeese,
Sonja E. Singletary,
Richard L. Theriault
From the Section of Endocrinology, Departments of Breast and Gynecologic Medical Oncology, Radiation Oncology, and Surgical Oncology, M.D. Anderson Cancer Center, University of Texas, Houston, TX.
Address reprint requests to Rena Vassilopoulou-Sellin, MD, Section of Endocrinology, Box 15, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030; email rsellin{at}notes.mdacc.tmc.edu
PURPOSE: To determine whether estrogen replacement therapy (ERT) alters the development of new or recurrent breast cancer in women previously treated for localized breast cancer.
PATIENTS AND METHODS: Potential participants (n = 319) in a trial of ERT after breast cancer were observed prospectively for at least 2 years whether they enrolled onto the randomized trial or not. Of 319 women, 39 were given estrogen and 280 were not given hormones. Tumor size, number of lymph nodes, estrogen receptors, menopausal status at diagnosis, and disease-free interval at the initiation of the observation period were comparable for the trial participants (n = 62) versus nonparticipants (n = 257) and for women on ERT (n = 39) versus controls (n = 280). Cancer events were ascertained for both groups.
RESULTS: Patient and disease characteristics were comparable for the trial participants versus nonparticipants, as well as for the women on ERT versus the controls. One patient in the ERT group developed a new lobular estrogen receptor–positive breast cancer 72 months after the diagnosis of a ductal estrogen receptor–negative breast cancer and 27 months after initiation of ERT. In the control group, there were 20 cancer events: 14 patients developed new or recurrent breast cancer at a median time of 139.5 months after diagnosis and six patients developed other cancers at a median time of 122 months.
CONCLUSION: ERT does not seem to increase breast cancer events in this subset of patients previously treated for localized breast cancer. Results of randomized trials are needed before any changes in current standards of care can be proposed.
Coauthors' names are listed in alphabetical order.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
C. Antoine, F. Liebens, B. Carly, A. Pastijn, S. Neusy, and S. Rozenberg
Safety of hormone therapy after breast cancer: a qualitative systematic review
Hum. Reprod.,
February 1, 2007;
22(2):
616 - 622.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N Angelopoulos, V Barbounis, S Livadas, D Kaltsas, and G Tolis
Effects of estrogen deprivation due to breast cancer treatment
Endocr. Relat. Cancer,
September 1, 2004;
11(3):
523 - 535.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. E. Smith and M. Dowsett
Aromatase Inhibitors in Breast Cancer
N. Engl. J. Med.,
June 12, 2003;
348(24):
2431 - 2442.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. H. Humphries and S. Gill
Risks and benefits of hormone replacement therapy: The evidence speaks
Can. Med. Assoc. J.,
April 15, 2003;
168(8):
1001 - 1010.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. D. Shanafelt, D. L. Barton, A. A. Adjei, and C. L. Loprinzi
Pathophysiology and Treatment of Hot Flashes
Mayo Clin. Proc.,
November 1, 2002;
77(11):
1207 - 1218.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. I. Pritchard, H. Khan, and M. Levine
Clinical practice guidelines for the care and treatment of breast cancer: 14. The role of hormone replacement therapy in women with a previous diagnosis of breast cancer
Can. Med. Assoc. J.,
April 1, 2002;
166(8):
1017 - 1022.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Messina and C. L. Loprinzi
Soy for Breast Cancer Survivors: A Critical Review of the Literature
J. Nutr.,
November 1, 2001;
131(11):
3095S - 3108.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. I. Pritchard
Hormone Replacement in Women with a History of Breast Cancer
Oncologist,
August 1, 2001;
6(4):
353 - 362.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. L. Shapiro and A. Recht
Side Effects of Adjuvant Treatment of Breast Cancer
N. Engl. J. Med.,
June 28, 2001;
344(26):
1997 - 2008.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. S. O'Meara, M. A. Rossing, J. R. Daling, J. G. Elmore, W. E. Barlow, and N. S. Weiss
Hormone Replacement Therapy After a Diagnosis of Breast Cancer in Relation to Recurrence and Mortality
J Natl Cancer Inst,
May 16, 2001;
93(10):
754 - 761.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. F. Col, L. K. Hirota, R. K. Orr, J. K. Erban, J. B. Wong, and J. Lau
Hormone Replacement Therapy After Breast Cancer: A Systematic Review and Quantitative Assessment of Risk
J. Clin. Oncol.,
April 15, 2001;
19(8):
2357 - 2363.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. J. Burstein and E. P. Winer
Primary Care for Survivors of Breast Cancer
N. Engl. J. Med.,
October 12, 2000;
343(15):
1086 - 1094.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. L. Loprinzi and D. Barton
Estrogen Deficiency: In Search of Symptom Control and Sexuality
J Natl Cancer Inst,
July 5, 2000;
92(13):
1028 - 1029.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Managing Menopausal Symptoms in Women with Breast Cancer
Journal Watch Women's Health,
July 1, 2000;
2000(701):
20 - 20.
[Full Text]
|
|
|
|
|
|
|
J. M Dopp and J. M Kolesar
Risk of breast cancer associated with hormone replacement therapy
Journal of Oncology Pharmacy Practice,
September 1, 1999;
5(3):
109 - 116.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Postmenopausal Estrogens After Breast Cancer Treatment
Journal Watch (General),
May 28, 1999;
1999(528):
2 - 2.
[Full Text]
|
|
|
|
